Key result
A 56-year-old man with giant cell myocarditis presented with rapidly progressive conduction abnormalities and fulminant heart failure requiring a ventricular assist device.
Why the study?
Giant cell myocarditis is rapidly progressive and frequently fatal without early diagnosis and prompt immunosuppression or transplantation.
Case Report (n=1)
Giant cell myocarditis is a rapidly progressive and frequently fatal disease that should be considered in cardiomyopathy of unknown etiology, as early immunosuppression may prevent catastrophic outcomes.
This fulminant GCM case with VAD requirement warrants early diagnostic vigilance in unexplained cardiomyopathy; leaves open optimal immunosuppression timing and efficacy.
Giant cell myocarditis (GCM) usually affects previously healthy adults and is a rapidly progressive and frequently fatal disease. It has a median survival of 3 months to death or transplant without appropriate therapy. Hence, early diagnosis is critical, with evidence showing rapidly instituted cyclosporine-based immunosuppression can improve transplant-free survival. Although transplant is an effective strategy, GCM can recur in 25% of transplanted hearts. We present a case of GCM in a patient who presented with conduction abnormalities and fulminant heart failure.
No takes yet. Share an insight, caveat, or question.
Gadela et al. (2021) conducted a case report in Giant cell myocarditis (n=1). High-dose steroids and tacrolimus was evaluated. A 56-year-old man with giant cell myocarditis presented with rapidly progressive conduction abnormalities and fulminant heart failure requiring a ventricular assist device.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: